Studies (references) |
Study types |
No. of
patients |
Offending agents |
Follow-up |
End
points |
Sheppard et al. (37) |
Retrospective descriptive case study |
Two |
Anthracycline |
Six months |
Fair recovery of NYHA functional class,
normalization of NT-proBNP concentration, no re-hospitalization for
heart failure |
Canale et al. (38) |
Prospective descriptive case study |
Four |
Anthracycline or carfilzomib |
One/Six/Twelve months |
Fair recovery of
NYHA functional class, reverse remodeling of ventricular size, no
re-hospitalization for heart failure |
Frey et al. (39) |
Pilot study |
Twenty-one |
Antineoplastic
agents and radiation |
Twelve months |
Significant improvement in NYHA
functional class and NT-proBNP levels |
MartÃn-Garcia et al. (40) |
Retrospective multicenter registry
study |
Sixty-seven |
Wide-ranging antineoplastic agents or (and)
thoracic radiotherapy |
Median: 4.6 [IQR 1-11] months |
Fair recovery of NYHA functional class, NT-proBNP
concentration, echocardiographic functional
and structural
parameters
|
Renato et al. (41) |
Descriptive case study |
Two |
Anthracycline |
Four/Twenty-four months |
Fair recovery of NYHA
functional class, NT-proBNP concentration, echocardiographic
functional
and structural parameters
|
Ana et al. (42) |
Retrospective multicentre registry study |
Ten |
Wide-ranging antineoplastic agents |
For at least 3 months |
Fair
recovery of NYHA functional class, NT-proBNP concentration, LVEF and LV
remodelling |
Gregorietti et al. (43) |
Prospective registry study |
Twenty-eight |
Anthracycline or with anti-HER2 therapies |
Median:
Twenty months |
Fair recovery of NYHA functional
class, NT-proBNP concentration, echocardiographic
functional
and structural parameters
|
Xi et al. (47) |
Descriptive case study |
One |
Anthracycline and
trastuzumab |
Four months |
Normalization of LVEF
and
NT-proBNP concentration
|
Lupi et al. (48) |
Descriptive case study |
One |
Rituximab |
Twelve months |
Durable improvement of symptoms, LVEF and NT-proBNP
concentration |
Wu et al. (49) |
Descriptive case study |
One |
Immuno-checkpoint
inhibitor |
Two months |
Certain recovery of NYHA
functional class, cardiac functional
and structural
parameters
|
PRADA II trial (50) |
A randomized, double blind, multi-center, clinical
trial |
214 patients |
(neo-)adjuvant
chemotherapy
with epirubicin independently of additional
trastuzumab/pertuzumab treatment
|
At baseline, at end of
anthracycline treatment and following 18 months after enrolment |
The
primary outcome: LVEF by CMR from baseline to 18 months. Secondary
outcomes: change in LV function by global longitudinal strain by CMR and
echocardiography and change in circulating cardiac troponin
concentrations. |
Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal
pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left
ventricular ejection fraction; CMR, cardiac magnetic resonance. |
Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal
pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left
ventricular ejection fraction; CMR, cardiac magnetic resonance. |
Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal
pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left
ventricular ejection fraction; CMR, cardiac magnetic resonance. |
Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal
pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left
ventricular ejection fraction; CMR, cardiac magnetic resonance. |
Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal
pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left
ventricular ejection fraction; CMR, cardiac magnetic resonance. |
Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal
pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left
ventricular ejection fraction; CMR, cardiac magnetic
resonance. |